However, this therapeutic avenue requires further exploration, as a Phase II clinical trial of PEGylated IL-10 (pegilodecakin) combined with ICIs in metastatic NSCLC (NCT03382899/NCT03382912) failed to meet its primary endpoint, highlighting the complexity of its clinical application [52]. This evidence concerns the gene IL10 and non-small cell lung carcinoma.